Modeling the renoprotective mechanisms of SGLT2 inhibition in hypertensive chronic kidney disease

Sodium‐glucose cotransporter (SGLT)‐2 inhibitors have recently been approved for chronic kidney disease (CKD) based on their ability to lower proteinuria and slow CKD progression independent of diabetes status. In diabetic renal disease, modulation of tubuloglomerular feedback (TGF) leading to lower...

Descripción completa

Detalles Bibliográficos
Autores principales: Clemmer, John S., Yen, Timothy E., Obi, Yoshitsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643202/
https://www.ncbi.nlm.nih.gov/pubmed/37957121
http://dx.doi.org/10.14814/phy2.15836

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643202/
https://www.ncbi.nlm.nih.gov/pubmed/37957121
http://dx.doi.org/10.14814/phy2.15836

Ejemplares similares